Add-on Clioquinol in drug-resistant epilepsy: an exploratory study
Key facts
- Where
- Leuven, BelgiumSee the site
- Phase
- 2. fázis
Where in Belgium
- UZ LeuvenLeuven, BelgiumNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UZ Leuven
- Trial code
- EU 2024-511388-27-04
- Record updated
- 2025. október 29.
- Original description
To study whether add-on clioquinol decreases the seizure frequency and severity in patients with drug-resistant epilepsy.Read full original descriptionShow less
To study whether add-on clioquinol decreases the seizure frequency and severity in patients with drug-resistant epilepsy.
Inclusion: Drug-resistant epilepsy: ≥ 4 seizures in the 2 week prospective period (baseline) before visit 2, not all (4) seizures observed in 1 of the 2 weeks. Baseline period can be extended with 1 or 2 weeks; Age ≥ 12 years and < 35 years at time of inclusion; Drug-resistant epilepsy: before inclusion failure of at least 2 AEDs; The patient is at the moment of inclusion on max 4 anti-epileptic drugs (VNS and ketogenic diet not included); Well defined epilepsy history with convulsive seizures (with observable and countable motor component).
Exclusion: Presence of C609T NQO1 SNP after SNP analysis of NQO1 based on a blood sample during baseline visit (visit 1) by Genomics Core; Asian etnicity; Abnormal low blood level of vitamin B12 or Zn.